Standards of care issues with anticoagulation in real-world populations

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Anticoagulants are recommended for nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE).
• Warfarin, the standard anticoagulant, often has suboptimal International Normalized Ratio (INR) control, impacting patient outcomes.
• Real-world patient populations, especially those with comorbidities, present challenges for anticoagulation management.

Purpose of the Study:

• To review the challenges and considerations in anticoagulation therapy for NVAF and VTE.
• To highlight the importance of optimizing INR control and surveillance during anticoagulation.
• To discuss the potential role of novel oral anticoagulants as alternatives to warfarin.

Main Methods:

• Review of current guidelines and clinical practices for anticoagulation in NVAF and VTE.
• Analysis of factors affecting INR control and patient outcomes with warfarin.
• Discussion of complexities in managing anticoagulation in patients with comorbidities.

Main Results:

• Suboptimal INR control with warfarin is a persistent issue, even in clinical trials.
• Early recurrence of VTE necessitates vigilant surveillance and prompt anticoagulation optimization.
• Patients with multiple comorbidities pose significant challenges to effective anticoagulation management.

Conclusions:

• Optimizing anticoagulation therapy, including INR control and surveillance, is critical for improving outcomes in NVAF and VTE.
• Aligning financial incentives and enhancing care coordination are vital for better anticoagulation management.
• The complexities of warfarin therapy and the rise of value-based care may drive the adoption of novel oral anticoagulants.